KR102576571B1 - 항염증 펩티드, 및 그의 용도 - Google Patents

항염증 펩티드, 및 그의 용도 Download PDF

Info

Publication number
KR102576571B1
KR102576571B1 KR1020217030710A KR20217030710A KR102576571B1 KR 102576571 B1 KR102576571 B1 KR 102576571B1 KR 1020217030710 A KR1020217030710 A KR 1020217030710A KR 20217030710 A KR20217030710 A KR 20217030710A KR 102576571 B1 KR102576571 B1 KR 102576571B1
Authority
KR
South Korea
Prior art keywords
leu
glu
gln
arg
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217030710A
Other languages
English (en)
Korean (ko)
Other versions
KR20210120134A (ko
Inventor
노라 칼디
시릴 로페즈
알레산드로 아들레피오
Original Assignee
뉴리타스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15177013.8A external-priority patent/EP3118215A1/en
Priority claimed from EP15177017.9A external-priority patent/EP3118216A1/en
Application filed by 뉴리타스 리미티드 filed Critical 뉴리타스 리미티드
Priority to KR1020237030244A priority Critical patent/KR20230132623A/ko
Publication of KR20210120134A publication Critical patent/KR20210120134A/ko
Application granted granted Critical
Publication of KR102576571B1 publication Critical patent/KR102576571B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020217030710A 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도 Active KR102576571B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237030244A KR20230132623A (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP15177013.8 2015-07-16
EP15177017.9 2015-07-16
EP15177013.8A EP3118215A1 (en) 2015-07-16 2015-07-16 Anti-inflammatory peptides, and uses thereof
EP15177017.9A EP3118216A1 (en) 2015-07-16 2015-07-16 Cellular growth and proliferation promoting peptides, and uses thereof
KR1020187004160A KR102307260B1 (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도
PCT/EP2016/067090 WO2017009484A1 (en) 2015-07-16 2016-07-18 Anti-inflammatory peptides, and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187004160A Division KR102307260B1 (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237030244A Division KR20230132623A (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20210120134A KR20210120134A (ko) 2021-10-06
KR102576571B1 true KR102576571B1 (ko) 2023-09-11

Family

ID=56686757

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237030244A Withdrawn KR20230132623A (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도
KR1020217030710A Active KR102576571B1 (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도
KR1020187004160A Active KR102307260B1 (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020237030244A Withdrawn KR20230132623A (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187004160A Active KR102307260B1 (ko) 2015-07-16 2016-07-18 항염증 펩티드, 및 그의 용도

Country Status (12)

Country Link
US (4) US10463591B2 (OSRAM)
EP (3) EP3747425A1 (OSRAM)
JP (3) JP2018523703A (OSRAM)
KR (3) KR20230132623A (OSRAM)
CN (2) CN114835784B (OSRAM)
AU (2) AU2016293129B2 (OSRAM)
BR (1) BR112018000660A2 (OSRAM)
CA (1) CA2992378A1 (OSRAM)
DK (1) DK3322430T3 (OSRAM)
ES (1) ES2806989T3 (OSRAM)
MX (2) MX377692B (OSRAM)
WO (1) WO2017009484A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504714A (ja) * 2016-12-05 2020-02-13 ニューリタス リミテッド ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
JP7340314B2 (ja) * 2020-01-15 2023-09-07 Tdk株式会社 米に含まれるタンパク質の含有量を測定する方法
KR102354916B1 (ko) * 2020-02-11 2022-01-26 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도
FR3114744B1 (fr) * 2020-10-02 2024-01-05 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer le confort de la peau et/ou des muqueuses et/ou l’apparence des phanères
WO2022131820A1 (ko) * 2020-12-16 2022-06-23 아주대학교산학협력단 아토피 피부염 예방 또는 치료용 항염증 펩타이드
CN114478702B (zh) * 2022-04-06 2023-12-12 中南林业科技大学 一种米糠来源短肽及其在治疗皮肤损伤中的应用
CN116253782B (zh) * 2022-09-08 2024-06-04 浙江大学 一种广谱抗菌肽ktr及其应用
CN116375828B (zh) * 2022-09-08 2024-06-04 浙江大学 一种具有抗菌活性的抗菌肽kta及其应用
FR3141066A1 (fr) * 2022-10-24 2024-04-26 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer la matrice extracellulaire du derme de la peau et/ou des muqueuses
CN116491631B (zh) * 2023-05-26 2024-06-25 青岛农业大学 一种预制菜红烧肉及其制备方法
WO2024259556A1 (en) * 2023-06-19 2024-12-26 Viage Therapeutics, Inc. Uses of therapeutic peptides
CN118812660A (zh) * 2023-06-29 2024-10-22 长沙理工大学 一种米渣蛋白源免疫抑制肽及其应用
WO2025133189A1 (en) * 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
EP4666996A1 (en) * 2024-06-21 2025-12-24 Quiris Healthcare GmbH & Co. KG Composition containing peptides of vegetable origin
CN120590476A (zh) * 2025-08-06 2025-09-05 浙江诺衍生物科技有限公司 一种有助于降血糖的七肽及其应用
CN120574921A (zh) * 2025-08-06 2025-09-02 浙江诺衍生物科技有限公司 一种有助于降血糖的大米肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2004042026A2 (en) 2002-11-04 2004-05-21 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
US20040123343A1 (en) 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2009026622A1 (en) 2007-08-24 2009-03-05 Mylexa Pty Limited Modulators of hypersensitivity reactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
DK0575443T3 (da) 1991-03-07 1997-12-29 Novo Nordisk As Ærteproteinhydrolysat, fremgangsmåde til dets fremstilling og anvendelse deraf
US5516642A (en) 1992-11-16 1996-05-14 Bristol-Myers Squibb Company Polypeptides derived from major histocompatibility complex Class I antigen
JP2673659B2 (ja) 1994-02-11 1997-11-05 株式会社ホーネンコーポレーション ペプチド
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
IT1313572B1 (it) 1999-07-27 2002-09-09 Enichem Spa Procedimento per la preparazione di epossidi.
JP2001335596A (ja) 2000-05-24 2001-12-04 Kenji Sakamoto 新規ペプチド及びその医薬用途
EP1415137A4 (en) 2001-04-17 2007-04-25 Ista S P A METHODS FOR MASS SPECTROMETRY DETECTION AND QUANTIFICATION OF SPECIFIC TARGET PROTEINS IN COMPLEX BIOLOGICAL SAMPLES
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
AU2004270102B2 (en) 2003-05-23 2009-10-01 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
AU2006263332B2 (en) 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
KR100759495B1 (ko) 2006-02-17 2007-09-18 재단법인서울대학교산학협력재단 친수성 생리활성 펩타이드와 소수성 물질을 포함한자기조립 나노구조체
CA2649842C (en) 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient
US9034402B2 (en) 2007-04-16 2015-05-19 Solae, Llc Protein hydrolysate compositions having improved sensory characteristics and physical properties
EP2698433A1 (en) 2007-06-06 2014-02-19 Monsanto Technology LLC Genes and uses for plant enhancement
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
US20120157395A1 (en) * 2009-07-13 2012-06-21 Masahisa Ibuki Anti-inflammatory agent for oral application, and anti-inflammatory peptide for oral application
WO2011122937A1 (en) 2010-03-29 2011-10-06 N.V. Nutricia Pea protein peptides with anti helicobacter pylori activity
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
WO2013092851A1 (en) * 2011-12-21 2013-06-27 Laboratorios Ordesa, S.L. Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
CA2897742A1 (en) * 2013-02-19 2014-08-28 Danone, S.A. Functional peptides for obesity disorders
DE202015009464U1 (de) 2014-12-04 2017-09-25 Mary Kay Inc. Kosmetikzusammensetzungen
US20170183386A1 (en) 2015-07-16 2017-06-29 Nuritas Limited Peptides, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20040123343A1 (en) 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2004042026A2 (en) 2002-11-04 2004-05-21 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
WO2009026622A1 (en) 2007-08-24 2009-03-05 Mylexa Pty Limited Modulators of hypersensitivity reactions

Also Published As

Publication number Publication date
JP2018523703A (ja) 2018-08-23
CA2992378A1 (en) 2017-01-19
US20220233425A1 (en) 2022-07-28
DK3322430T3 (da) 2020-06-29
US11253456B2 (en) 2022-02-22
CN108348568A (zh) 2018-07-31
AU2016293129B2 (en) 2021-01-28
JP7288026B2 (ja) 2023-06-06
US20190029939A1 (en) 2019-01-31
JP2023109950A (ja) 2023-08-08
US20240238184A1 (en) 2024-07-18
JP7739355B2 (ja) 2025-09-16
KR102307260B1 (ko) 2021-10-01
CN114835784A (zh) 2022-08-02
AU2016293129A1 (en) 2018-02-01
EP3322430B1 (en) 2020-03-25
ES2806989T3 (es) 2021-02-19
AU2021202423A1 (en) 2021-05-13
US20200060956A1 (en) 2020-02-27
US10463591B2 (en) 2019-11-05
KR20230132623A (ko) 2023-09-15
MX377692B (es) 2025-03-10
CN114835784B (zh) 2025-06-13
KR20180029237A (ko) 2018-03-20
CN108348568B (zh) 2021-12-28
MX2018000697A (es) 2018-08-15
US11779531B2 (en) 2023-10-10
KR20210120134A (ko) 2021-10-06
EP3747425A1 (en) 2020-12-09
MX2020010806A (es) 2020-10-28
JP2022009415A (ja) 2022-01-14
EP3322430A1 (en) 2018-05-23
EP3954700A1 (en) 2022-02-16
WO2017009484A1 (en) 2017-01-19
BR112018000660A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
KR102576571B1 (ko) 항염증 펩티드, 및 그의 용도
KR102551575B1 (ko) 글루코스 운반을 촉진하는데 사용하기 위한 펩티드
US10925922B2 (en) Growth promoting peptides, and uses thereof
HK40069687A (en) Anti-inflammatory peptides derived from rice proteins (oryza sativa) and uses thereof
HK40061519A (en) Growth promoting peptides and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301